Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Stavroula Masouridi‐Levrat"'
Autor:
Sarah Morin, Filippo Boroli, Sophie Vandenberghe‐Durr, Daniele Allali, Stavroula Masouridi‐Levrat, Yves Chalandon, Federico Simonetta
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 603-606 (2024)
Abstract Anaphylactic reactions at the time of chimeric antigen receptor T (CAR‐T) cell infusion are adverse events that have not been reported in pivotal clinical trials or in real‐world series. We report the case of patient with severe anaphyla
Externí odkaz:
https://doaj.org/article/931fed2a285943d9a4aec227190da80c
Autor:
Dietger Niederwieser, Dirk Hasenclever, Wolfgang Berdel, Bart J. Biemond, Haifa Al-Ali, Yves Chalandon, Michel van Gelder, Christian Junghanß, Gösta Gahrton, Mathias Hänel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jacob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Leo F. Verdonck, Vladan Vucinic, Bob Löwenberg, Jan Cornelissen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged
Externí odkaz:
https://doaj.org/article/e24e854d3915489f8bfdf3f02374efc6
Autor:
Dominik Heim, Helen Baldomero, Michael Medinger, Stavroula Masouridi-Levrat, Urs Schanz, Gayathri Nair, Tayfun Güngör, Jörg Halter, Jakob R. Passweg, Yves Chalandon, Swiss Stem Cell Transplantation Group (SBST)
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 5 (2024)
AIM: Until the year 2000, allogeneic haematopoietic cell transplantation (HCT) was the standard treatment for young and fit chronic myeloid leukaemia (CML) patients. CML was the main indication for allogeneic HCT. The introduction of tyrosine kinase
Externí odkaz:
https://doaj.org/article/e094cf77c51f4bccbbba9ae93266b65f
Autor:
Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programm
Externí odkaz:
https://doaj.org/article/cbfb749dbff44cd88f3e883f56499b63
Autor:
Ekaterina Rebmann, Mitja Nabergoj, Bastien Grandjean, Paraskevi Stakia, Alix Stern, Michael Medinger, Stavroula Masouridi‐Levrat, Carole Dantin, Urs Schanz, Helen Baldomero, Jakob Passweg, Gayathri Nair, Alicia Rovo, Yves Chalandon
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 258-261 (2023)
Abstract Due to relatively high nonrelapse mortality (NRM), allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in non‐Hodgkin's lymphoma (NHL) remains the ultimate line of treatment but the only curable approach in a setting of relaps
Externí odkaz:
https://doaj.org/article/8c5e8e9b1496437db78fb82e285918eb
Autor:
Helena Simeunovic, Martina Dickenmann, Mitja Nabergoj, Helen Baldomero, Stavroula Masouridi‐Levrat, Gayathri Nair, Urs Schanz, Jacob Passweg, Alicia Rovo, Yves Chalandon, Ekaterina Rebmann
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 262-265 (2023)
Abstract Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising in
Externí odkaz:
https://doaj.org/article/ca34f888599049ba8011b94a18ef2ad3
Publikováno v:
Thrombosis Journal, Vol 20, Iss 1, Pp 1-4 (2022)
Abstract Background Some conventional vaccines have been recognized as a cause of secondary immune thrombocytopenia (ITP). According to recent publications, mRNA vaccines are probably associated with an increased risk of ITP. Case presentation Our pa
Externí odkaz:
https://doaj.org/article/06d80d70b10240c8a50d0596d3fc14ee
Autor:
Davide Bosetti, Chiara Bernardi, Geoffrey Merle, Laetitia C Dubouchet, Stavroula Masouridi-Levrat, Yves Chalandon, Dionysios Neofytos
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 15, Iss 1 (2023)
# Introduction This case report illustrates the diagnostic challenges and complexities in the treatment of disseminated fusariosis. # Case Presentation An 18-year-old patient received a second allogeneic hematopoietic stem cell transplant (HSCT) 5
Externí odkaz:
https://doaj.org/article/de520e5f25b14ec282b45391003a0b98
Autor:
Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Amandine Pradier, Stavroula Masouridi-Levrat, Federico Simonetta, Yves Chalandon
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Sorafenib significantly improves survival of FLT3-ITD mutated AML patients when used as a post-allogeneic HSCT maintenance. Importantly, clinical trials reported a low rate of toxicities requiring sorafenib discontinuation. The aim of our analysis wa
Externí odkaz:
https://doaj.org/article/4112719bae8044f9936b6400c0213214
Autor:
Amandine Pradier, Samuel Cordey, Marie-Céline Zanella, Astrid Melotti, Sisi Wang, Anne-Claire Mamez, Yves Chalandon, Stavroula Masouridi-Levrat, Laurent Kaiser, Federico Simonetta, Diem-Lan Vu
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
IntroductionHuman pegivirus-1 (HPgV-1) is a so-called commensal virus for which no known associated organ disease has been found to date. Yet, it affects immune-reconstitution as previously studied in the HIV population, in whom active co-infection w
Externí odkaz:
https://doaj.org/article/1f5a8acfc27c41fcb7aef942c4a97a9b